All Insights and Resources

Allogeneic

$Beam Therapeutics Announced First Patient Dosed in Phase I/II Trial in Relapsed, Refractory T-ALL/T-LL$

6 September 2023

Beam Therapeutics Announced First Patient Dosed in Phase I/II Trial in Relapsed, Refractory T-ALL/T-LL

Beam Therapeutics Announced First Patient

Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization

24 August 2023

Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization

Cellares has secured $255 million

Precision BioSciences Completes Strategic $227M Transaction with Imugene for CAR-T Therapy

17 August 2023

Precision BioSciences Completes Strategic $227M Transaction with Imugene for CAR-T Therapy

Precision BioSciences Completes Strategic Transaction

Kyverna’s Series B Financing Round Extends to $145M

3 August 2023

Kyverna’s Series B Financing Round Extends to $145M

Kyverna Therapeutics has oversubscribed its

POPULAR NEWS ITEMS

21 September 2023

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

20 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

First Type 1 Diabetes Cell Therapy Approved by the FDA

28 July 2023

First Type 1 Diabetes Cell Therapy Approved by the FDA

The FDA has approved the

First Allogeneic Stem Cell Transplant Therapy Approved by the FDA

19 April 2023

First Allogeneic Stem Cell Transplant Therapy Approved by the FDA

Cell therapy pioneer Gamida Cell

Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors

8 March 2023

Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors

Adaptimmune Theraputics and TCR2 Theraputics

Mesoblast Phase III Cell Therapy Shows Promise Against Heart Failure

28 February 2023

Mesoblast Phase III Cell Therapy Shows Promise Against Heart Failure

Mesoblast has announced that the

RECOMENDED TOPICS

Tissue Engineering

Viral/Non-Viral Vectors

POPULAR NEWS ITEMS

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

logo_mobile_footer

Company

Resources

Network

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022